Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kensuke Naito

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
International Journal of Hematology|March 15, 2006
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agentAkihiro Takeshita, Kaori Shinjo, Kensuke Naito, et al.
Transplantation and Cellular Therapy|January 24, 2024
A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic LymphohistiocytosisHaryoon Kim, Kota Mizuno, Kyoko Masuda, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|July 1, 2021
A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphomaKazunori Ohnishi, Ken Ohmachi, Kiyoshi Ando, et al.
International Journal of Hematology|April 11, 2009
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative studyYukio Kobayashi, Kensei Tobinai, Akihiro Takeshita, et al.
Journal of Cancer Survivorship : Research and Practice|September 1, 2022
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantationSaiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori, et al.
Journal of Hematology|September 9, 2024
Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic AnemiaHirofumi Yokota, Kotaro Miyao, Masashi Sawa, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
International Journal of Hematology|March 15, 2006
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agentAkihiro Takeshita, Kaori Shinjo, Kensuke Naito, et al.
Transplantation and Cellular Therapy|January 24, 2024
A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic LymphohistiocytosisHaryoon Kim, Kota Mizuno, Kyoko Masuda, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|July 1, 2021
A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphomaKazunori Ohnishi, Ken Ohmachi, Kiyoshi Ando, et al.
International Journal of Hematology|April 11, 2009
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative studyYukio Kobayashi, Kensei Tobinai, Akihiro Takeshita, et al.
Journal of Cancer Survivorship : Research and Practice|September 1, 2022
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantationSaiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori, et al.
Journal of Hematology|September 9, 2024
Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic AnemiaHirofumi Yokota, Kotaro Miyao, Masashi Sawa, et al.
Pageof 4